Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinocelltech GroupSHSE:688520 -6.48%54 PB Ratio is 18.73 as of Jul. 24, 2026, which is 35% below its 10-year median of 28.74. GuruFocus rates SHSE:688520 with a GF Score™ of 54/100 and a GF Value™ of ¥36.52 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,230 Biotechnology companies, Sinocelltech Group ranks worse than 93.5% on this metric.
Sinocelltech Group Ltd stock PB Ratio (=20.14) is close to 10-year low of 18.31.
The historical rank and industry rank for Sinocelltech Group's PB Ratio or its related term are showing as below:
SHSE:688520'
s PB Ratio Range Over the Past 10 Years
Min: 18.31 Med: 28.74 Max: 343.01
Current: 18.76
During the past 10 years, Sinocelltech Group's highest PB Ratio was 343.01. The lowest was 18.31. And the median was 28.74.
SHSE:688520's PB Ratio is ranked worse than 93.5% of 1230
companies
in the Biotechnology industry
Industry Median: 2.82
vs SHSE:688520: 18.76
During the past 12 months, Sinocelltech Group's average Book Value Per Share Growth Rate was 292.60% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Sinocelltech Group was 43.90% per year. The lowest was -107.70% per year. And the median was -24.20% per year.
Back to Basics: PB Ratio
Sinocelltech Group (SHSE:688520) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Sinocelltech Group PB Ratio Related Terms
Sinocelltech Group PB Ratio Historical Data
* Premium members only.
The historical data trend for Sinocelltech Group's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688520 vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Sinocelltech Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinocelltech Group PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sinocelltech Group's PB Ratio distribution charts can be found below:
* The bar in red indicates where Sinocelltech Group's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Sinocelltech Group (SHSE:688520) has a PB Ratio of 18.73 as of Jul. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sinocelltech Group and its competitors. This is 35% below median its historical median of 28.74. Over the past decade, Sinocelltech Group's PB Ratio has ranged from 18.31 to 343.01. According to the industry distribution chart, Sinocelltech Group ranks #1150 out of 1230 companies in the Biotechnology industry, placing it in the top 93.5%.
Is Sinocelltech Group's PB Ratio too high?
Sinocelltech Group's current PB Ratio of 18.73 is 35% below median its 10-year median of 28.74. Over the past 10 years, this metric has ranged from a low of 18.31 to a high of 343.01. The Biotechnology industry median PB Ratio is 2.82. Sinocelltech Group's value of 18.73 is 564.2% above this industry median. Based on the distribution chart, Sinocelltech Group ranks #1150 out of 1230 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sinocelltech Group has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sinocelltech Group's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sinocelltech Group ranks #1150 out of 1230 companies for PB Ratio. This places Sinocelltech Group in the lower half of its industry. The industry median PB Ratio is 2.82. Sinocelltech Group's value of 18.73 is 564.2% above this benchmark. Historically, Sinocelltech Group's own PB Ratio has ranged from 18.31 to 343.01 over the past decade. While the company's 10-year median is 28.74 vs. the industry median of 2.82, Sinocelltech Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,230 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinocelltech Group's current PB Ratio of 18.73 is 564.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sinocelltech Group and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinocelltech Group's current PB Ratio is 18.73, which is 35% below median its own 10-year median of 28.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinocelltech Group stock overvalued right now?
Based on GuruFocus' analysis, Sinocelltech Group (SHSE:688520) is currently considered Fairly Valued. The stock's GF Value™ is ¥36.52, compared to a current price of ¥33.76 — trading 7.6% below its estimated fair value. The current PB Ratio is 18.73, which is 35% below median its 10-year median of 28.74 and 564.2% above the Biotechnology industry median of 2.82. Sinocelltech Group's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Sinocelltech Group (SHSE:688520), the current PB Ratio is 18.73 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinocelltech Group (SHSE:688520) Overvalued in 2026?
Based on GuruFocus' analysis, Sinocelltech Group stock appears to be undervalued.
The current stock price of ¥33.76 is trading 7.6% below its estimated GF Value™ of ¥36.52.
GuruFocus considers Sinocelltech Group to be Fairly Valued.
Key valuation signals for SHSE:688520:
PB Ratio: 18.73 (35% below median its 10-year median of 28.74)
GF Value™: ¥36.52 vs. price of ¥33.76 (7.6% below fair value)
Industry Position: 564.2% above the Biotechnology median (#1150 of 1230)
No single metric tells the full story. See the SHSE:688520 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinocelltech Group Ltd is one of Chin's biopharma companies specializing in biologics and vaccines. The company's therapeutic areas include oncology, immunology and inflammation, ophthalmology, and prophylactic vaccines. The company has developed technology platforms in protein expression vectors, cell line development, serum-free medium development, stoichiometrically controlled fed-batch cell culture, process scale-up, and protein purification. The capabilities of the company include stable CHO cell line development, cell banking and certification, serum-free and protein-free culture medium development, fed-batch cell culture process development, optimization, and process scale-up, protein purification development, and large scale production.
54GF Score
Get the complete analysis for SHSE:688520
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688520 has been successfully added to your 
